![]() |
市场调查报告书
商品编码
1284257
到 2028 年的输液泵软件市场预测——按类型(临床工作流程软件、减少剂量错误软件、互操作性软件)、按适应症、按应用、按最终用户、按地区分类的全球分析Infusion Pump Software Market Forecasts to 2028 - Global Analysis By Type (Clinical Workflow Software, Dose Error Reduction Software and Interoperability Software), Indication, Application, End User and By Geography |
根据 Stratistics MRC 的数据,2022 年全球输液泵软件市场将达到 9.635 亿美元,预计到 2028 年将达到 16.249 亿美元,预计复合年增长率为 9.1 2020 年的百分比。
一组称为输液泵的泵用于输送药物和营养物质等物质。 该软件控制液体传输的速度。 该软件还控制泵送机制和用户界面,以在安全等关键任务中保持同步。 该泵是一个外部设备。 泵通过动脉、静脉和皮下通路输送这些液体。 随着外科手术数量的增加,输液泵在这些国家的机会也在增加,这最终推动了对输液泵所用软件的需求。
根据《传染病顾问杂誌》,美国每年进行大约 2700 万次外科手术。
慢性病的增加和医院液体治疗成本的上升导致家庭输液解决方案的研发活动激增。 例如,越来越多的糖尿病、癌症和神经系统疾病患者需要长期护理,最好是在家中。 此外,老龄化社会对长期护理的需求正在推动针对家庭输液治疗的新产品的开发。
关于泵的製造和使用的法规正在收紧,从而减缓了新设备的审批流程。 因此,预计市场的扩张将被推迟。 此外,由于製造错误导致产品召回的增加也阻碍了市场扩张。 例如,2019 年 8 月,由于输液警报、低优先级保持静脉开放 (KVO) 和多个软件错误,我们召回了 Vigilant Agilia 药物库和 Volume MC Agilia 输液泵。
门诊泵是各种医疗环境中给药的重要工具。 在对医院和家中的患者进行止痛药、化学疗法、液体和其他治疗时,它是必不可少的。 在发达国家,随着在现场进行长期护理以减轻与医院管理相关的经济限制,预计在不久的将来门诊泵的市场将会增长。
单位、10 的倍数、计算错误和按钮错误是最常见的输液问题。 在对输液泵进行编程时,少量错别字可能会造成灾难性后果。 为了解决这些问题并将当前的智能泵推进到一个新的“智能”输液系统水平,输液泵和条码药物管理(BCMA)系统、医院信息系统(HIS)、电子病历(EMR))需要无线连接。 由于无线连接不佳和医院支出限制,大多数医院的智能输液设备和医院信息系统不兼容,输液泵市场面临重大障碍。
COVID-19 大流行的影响及其持续时间的不确定性显着提高了该行业的增长率。 2020 年 COVID-19 测试的增加在很大程度上是罪魁祸首。 然而,COVID-19 疫情导致劳动力短缺和供应链中断,导致产量下降。 主要利益相关者不断改变策略以应对快速变化的情况。 预计医疗保健行业将受到 COVID-19 的严重长期影响。 在这个问题得到解决之前,各国和利益相关者需要将医疗改革作为优先事项。
胰岛素输注部分预计将实现有利可图的增长,因为它以显着更高的增长率增长并保持其主导地位。 这是由于全球 1 型糖尿病患者的数量不断增加,以及胰岛素泵领域的技术发展前景广阔。 未来几年,PCA 泵在疼痛治疗中的广泛使用预计将增加全球产品需求。
由于最昂贵的输液设备、使用这些设施的患者数量巨大以及操作泵的熟练员工的可用性,预计医院部门在预测期内将以最快的复合年增长率增长。以及医院部门占据最大的市场份额。 然而,由于门诊泵的使用增加以及对护理点管理以减轻成本负担的需求不断增长,家庭护理环境领域的份额正在增加。
北美输液泵软件市场目前的扩张意义重大,因为家庭医疗保健行业、患者和医生不断采用新的尖端解决方案来进行慢性病的常规管理。被认为是负责任的,预计将保持预测期内的最高市场份额。 由于患者意识的提高、慢性病患病率上升、手术数量增加以及控制不断上升的医疗保健成本的需要,输液泵软件在该地区经历了显着增长。
预计亚太地区将在预测期内呈现最高的复合年增长率。 然而,随着主要公司专注于进一步扩大其基地,预计这些地区的市场将扩大。
2023 年 5 月,百特签署了最终协议,以 42.5 亿美元的价格将其生物製药解决方案业务出售给 Advent International 和 Warburg Pincus。
2023 年 4 月,百特将在美国推出 Zosyn Premix。 Zosyn Premix 适用于治疗由敏感细菌引起的多重感染,并以 Baxter 独有的单剂量 Galaxy 容器提供。
According to Stratistics MRC, the Global Infusion Pump Software Market is accounted for $963.5 million in 2022 and is expected to reach $1,624.9 million by 2028 growing at a CAGR of 9.1% during the forecast period. A group of pumps called infusion pumps are used to transport substances like medications and nutrition. Software controls the rates at which the fluids are transferred. The software also controls the pumping mechanism to maintain the pace and the user interface, among other crucial tasks like safety. These pumps are outside equipment. The pump moves these fluids through arterial, intravenous, and subcutaneous pathways. This rising trend of the number of surgical procedures performed is indicating that there is a growing opportunity for the infusion pumps in such countries which is ultimately driving the demand for the software used for infusion pump.
According to the Journal of Infectious Disease Adviser, approximately 27 million surgical procedures are performed in the United States each year.
Growing research and development efforts are being made to create home-based infusion solutions as a result of the rising prevalence of chronic illnesses and the rising expense of hospital-based infusion therapies. For instance, an increasing number of people with diabetes, cancer, and neurological illnesses are in need of long-term care, preferably at home. Furthermore, the necessity for long-term care therapies among an ageing population is fuelling the development of new products aimed at home-based infusion therapies.
Regulations governing the manufacture and use of pumps are becoming more onerous, which slows down the approval process for new devices. This aspect is projected to slow market expansion. Additionally, a growing number of product recalls brought on by manufacturing mistakes are limiting market expansion. For example, recalled the Vigilant Agilia drug library and the Volume MC Agilia infusion pump in August 2019 due to infusion alarm, low priority keep vein open (KVO), and multiple software errors.
An important tool for medication administration in a variety of medical settings is the ambulatory pump. They are essential in giving patients analgesics, chemotherapy, TPN infusions, and other treatments in hospitals and at home. The market for portable pumps is projected to rise in the near future due to the move towards site of care management of chronic illnesses in industrialised nations in order to reduce the financial constraints associated with hospital-based management.
Unit, multiples of ten, computation, and push-button errors are some of the most typical infusion problems. When programming infusion pumps, decimal entry mistakes can have fatal consequence to address these issues and advance the present smart pumps to a new level of "intelligent" infusion systems, wireless connection of infusion pumps with the Barcoded Medication Administration (BCMA) system, the Hospital Information System (HIS), and the Electronic Medical Record (EMR) is necessary. The market for infusion pumps faces a substantial obstacle from the lack of compatibility between smart infusion devices and hospital information systems in most hospitals as a result of poor wireless connectivity and limited hospital spending.
The COVID-19 pandemic's effects and the uncertainty surrounding its longevity have caused a significant increase in the industry's growth rate. The rise in COVID-19 testing in 2020 is mostly to blame for this. However, there was a reduction in output as a result of the COVID-19 epidemic due to labour shortages and supply chain interruptions. Important parties are continuing to modify their tactics in response to the fast shifting circumstances. The healthcare sector is expected to see severe long-term effects from COVID-19. Prioritised healthcare reforms would need to be implemented by nations and significant stakeholders until the issue is resolved.
The insulin infusion segment is estimated to have a lucrative growth, due to increase at a noticeably high growth rate, maintaining its dominance. This is due to an increase in the number of type 1 diabetes patients worldwide and the development of promising technology in the area of insulin pumps. In the upcoming years, expanding PCA pump uses in pain treatment are projected to increase product demand globally.
The hospitals segment is anticipated to witness the fastest CAGR growth during the forecast period, due to the most expensive infusion devices, huge patient population using these facilities, and availability of skilled staff to operate the pump, the hospitals sector held the greatest share of the market. However, due to the rising use of ambulatory pumps and growing demand for site of care management to lower cost burden, the home care settings segment.
North America is projected to hold the highest market share during the forecast period owing to the home healthcare industry, patients, and doctors are largely to blame for the present expansion of the North American infusion pump software market as they consistently embrace new, cutting-edge solutions for the routine management of chronic medical conditions. Infusion pump software has seen significant growth in the region due to increased patient awareness, the rising prevalence of chronic diseases, and an increase in the number of surgeries performed there, and the need to rein in rising healthcare costs.
Asia Pacific is projected to have the highest CAGR over the forecast period, owing to some of the factors include the rise in the prevalence of chronic diseases like diabetes and cancer, expanding healthcare infrastructure, growing GDP, an increase in disposable income, and rising awareness of the accessibility of advanced therapies in the Asia Pacific region. However, the market in these regions will grow as major firms focus more on expanding their footprint.
Some of the key players profiled in the Infusion Pump Software Market include Baxter International, Becton, Dickinson and Company, B. Braun Medical Inc., FLOWONIX MEDICAL INC, Medtronic, Merck KGaA, Smiths Medical, Q Core Medical Ltd, Fresenius Kabi, ICU Medical Inc., Roche Diagnostics, Agilent Technologies, Terumo Medical, Micrel Medical Devices, Ypsomed and F. Hoffmann-La Roche
In May 2023, Baxter Signs Definitive Agreement to Divest its BioPharma Solutions Business to Advent International and Warburg Pincus for $4.25 Billion.
In April 2023, Baxter Launches Zosyn Premix in US, Zosyn premix is indicated for the treatment of multiple infections caused by susceptible bacteria and is available in Baxter's proprietary single-dose Galaxy containers.